eCTD Module 4: Nonclinical Study Reports and Data Organization

eCTD Module 4: Nonclinical Study Reports and Data Organization

Key Takeaways

Module 4 Structure

Complete Module 4 Organization per ICH M4S(R2)

Detailed Sub-Section Breakdown

4.2.1 Pharmacology:

4.2.2 Pharmacokinetics:

4.2.3 Toxicology:

Pharmacology Studies (4.2.1)

4.2.1.1: Primary Pharmacodynamics

Primary pharmacodynamic studies demonstrate the drug's mechanism of action and therapeutic effect using in vitro and in vivo models.

Typical studies placed in this section:

4.2.1.2: Secondary Pharmacodynamics

Secondary pharmacodynamic studies assess off-target pharmacological activity.

4.2.1.3: Safety Pharmacology

Safety pharmacology studies assess potential effects on vital organ systems per ICH S7A (core battery) and ICH S7B (QT/hERG assessment).

Core Battery (ICH S7A):

Supplemental Studies (ICH S7A, as warranted):

QT Assessment (ICH S7B):

The in vitro hERG channel assay and in vivo QT study are among the most critical nonclinical studies. ICH S7B requires assessment of the drug's potential to delay cardiac repolarization (QT prolongation), which can lead to fatal arrhythmias (Torsade de Pointes).

Pharmacokinetics Studies (4.2.2)

ADME Study Organization

The ADME (Absorption, Distribution, Metabolism, Excretion) studies in Module 4 characterize the drug's pharmacokinetic behavior in animal species and in vitro systems.

4.2.2.2 Absorption:

4.2.2.3 Distribution:

4.2.2.4 Metabolism:

4.2.2.5 Excretion:

4.2.2.7 Toxicokinetics:

Toxicokinetic (TK) data collected within toxicology studies are typically reported in the toxicology study report itself (Section 4.2.3.2) and cross-referenced here. TK data establishes systemic exposure at NOAEL doses, enabling safety margin calculations.

Toxicology Studies (4.2.3)

4.2.3.1: Single-Dose Toxicity

Under the 2010 revision of ICH M3(R2), standalone single-dose toxicity studies are no longer required for most pharmaceuticals. Information on acute toxicity can be derived from dose-escalation studies, dose-range-finding studies, or the highest-dose groups in repeat-dose studies.

However, single-dose study reports should still be placed in this section if they were conducted.

4.2.3.2: Repeat-Dose Toxicity

Repeat-dose studies are the cornerstone of the nonclinical safety assessment. ICH M3(R2) specifies the minimum duration of repeat-dose studies needed to support clinical trials and marketing:

Duration Requirements per ICH M3(R2):

Study Report Content (Typical):

4.2.3.3: Genotoxicity

Genotoxicity studies follow the ICH S2(R1) standard battery:

If any battery test is positive, follow-up studies are needed per ICH S2(R1) to characterize the finding and assess in vivo relevance.

4.2.3.4: Carcinogenicity

Carcinogenicity studies are required for drugs intended for chronic or frequent intermittent clinical use per ICH S1A. These are the longest and most expensive nonclinical studies.

ICH S1B(R1) now recommends a weight-of-evidence (WoE) approach for carcinogenicity assessment, allowing sponsors to justify whether a 2-year rat study is necessary based on genotoxicity, mechanism of action, and other factors.

“

Key Update: ICH S1B(R1), adopted in 2022, allows sponsors to use a weight-of-evidence-based assessment to determine whether a traditional 2-year rat carcinogenicity study is warranted, rather than defaulting to the conventional requirement. This can save 3-5 years of development time for appropriate products.

4.2.3.5: Reproductive and Developmental Toxicology

Reproductive toxicology studies follow ICH S5(R3) and are organized into three segments:

4.2.3.6: Local Tolerance

Local tolerance studies assess irritation and sensitization potential at the intended route of administration:

4.2.3.7: Other Toxicity Studies

This section accommodates specialized toxicology studies that do not fit the standard categories. Understanding the overall eCTD structure helps place these studies correctly:

Study Report Format

GLP Study Reports

All pivotal nonclinical safety studies (repeat-dose toxicology, genotoxicity, carcinogenicity, reproductive toxicology, safety pharmacology core battery) must be conducted under Good Laboratory Practice per 21 CFR Part 58.

GLP Study Report Elements (per 21 CFR 58.185):

Non-GLP Studies

Pharmacology studies (primary and secondary PD) and some PK studies are typically not conducted under GLP. However, study reports should still include:

• Clear study objectives and design
• Test article characterization
• Methods description
• Complete results
• Study director signature

Cross-Referencing Module 4 to Module 2

Module 4 study reports are summarized and interpreted in two Module 2 sections:

Cross-Referencing Best Practices

1. Use eCTD section numbers (e.g., 4.2.3.2) and study report numbers consistently
2. Ensure Module 2.6 tabulated summaries include every study in Module 4
3. Verify that NOAEL values, dose levels, and key findings are consistent between Module 2 and Module 4
4. Include hyperlinks from Module 2.4 narrative to Module 4 study reports in the eCTD

Common Module 4 Deficiencies

Key Regulatory References

References